Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Bryce Kirby"'
Autor:
Funda Meric-Bernstam, Turcin Saridogan, Argun Akcakanat, Ming Zhao, Kurt Evans, Erkan Yuca, Stephen Scott, Bryce Kirby, Xiaofeng Zheng, Min Jin Ha, Huiqin Chen, Patrick Ng, Tiimothy DiPeri, Gordon Mills, Jordi Rodon, Senthil Damodaran
The role of the fibroblast growth factor receptor (FGFR) gene alterations as therapeutic targets in breast cancer have not been well characterized. Futibatinib (TAS-120; Taiho) is a novel pan-FGFR inhibitor. We sought to determine the efficacy of fut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a9a4745eb75f67b68818b067517cb40
https://doi.org/10.21203/rs.3.rs-2248209/v1
https://doi.org/10.21203/rs.3.rs-2248209/v1
Autor:
Burak Uzunparmak, Cara Haymaker, Gabriela Raso, Chen Zhu, Serena Masciari, Lei Wang, Bryce Kirby, Heather Lin, Aysegul Gorur, Ann-Marie Cimo, Amber Kennon, Qingqing Ding, Andrea Palmieri, Gabriele Elizabeth Urschel, Ying Yuan, Guoxin Feng, Yasmeen Rizvi, Aisha Hussain, Vivek Subbiah, Timothy Anthony Yap, Jordi Rodon-Ahnert, Sarina Anne Piha-Paul, David S. Hong, Funda Meric-Bernstam, Ecaterina E. Dumbrava
Publikováno v:
Cancer Research. 83:961-961
Introduction: HER2 protein expression by immunohistochemistry (IHC) has been the main testing method for breast and gastric cancers. Much remains unknown about the frequency of HER2-low (IHC 1+ or 2+) expression and the change of HER2 status from pri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a9860d925ad26c9d62bc726d73b13ec
https://doi.org/10.1158/1538-7445.am2023-961
https://doi.org/10.1158/1538-7445.am2023-961
Autor:
Funda Meric-Bernstam, Alshad S. Lalani, Irmina Diala, Xiaofeng Zheng, Turcin Saridogan, Christian X. Cruz Pico, Bryce Kirby, Mehmet Esat Demirhan, Sarina Anne Piha-Paul, Scott Kopetz, Kurt W. Evans, Ming Zhao, Anil Korkut, Heping Wang, Stephen Scott, Erkan Yuca
Publikováno v:
Clin Cancer Res
Purpose: Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA approved for HER2-overexpressing/amplified (HER2+) breast cancer. In this preclinical study, we explored the efficacy of neratinib in combination with inhibitors of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a27ac887e0268acd217b52e06a13ac8
https://pubmed.ncbi.nlm.nih.gov/33414137
https://pubmed.ncbi.nlm.nih.gov/33414137
Autor:
Jordi Rodon, Timothy Philip DiPeri, Kurt W. Evans, Yasmin Rizvi, Huamin Wang, Filip Janku, Xiaofeng Zheng, Timothy A. Yap, Thuy M. Vu, Kenna R. Mills Shaw, Sun-Hee Kim, Funda Meric-Bernstam, Lawrence N. Kwong, Chetna Wathoo, Gabriela Raso, Hop S. Tran Cao, Michael P. Kahle, Dali Li, Bryce Kirby, Ching Wei D. Tzeng, Fei Su, Milind Javle
Publikováno v:
Cancer Research. 81:2710-2710
Purpose: Biliary tract cancers (BTCs), including intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC), are rare malignancies which frequently present at advanced stage and have a poor survival. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3a233f15e241fe0ecee83579cad2852
https://doi.org/10.1158/1538-7445.am2021-2710
https://doi.org/10.1158/1538-7445.am2021-2710
Autor:
Bryce Kirby, Scott Kopetz, Erkan Yuca, Kurt W. Evans, Ming Zhao, Turcin Saridogan, Sarina Anne Piha-Paul, Funda Meric-Bernstam, Irmina Diala, Stephen Scott, Mehmet Esat Demirhan, Alshad S. Lalani
Publikováno v:
Molecular Cancer Therapeutics. 18:B003-B003
Activation of HER2 signaling by amplification or overexpression of ERBB2 (HER2) is associated with the development and progression of breast cancer. Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor which selectively inhibits EGFR, HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a25a43bca262aec6533cfbc7bf1ea15b
https://doi.org/10.1158/1535-7163.targ-19-b003
https://doi.org/10.1158/1535-7163.targ-19-b003